

UNITY BIOTECHNOLOGY, INC.

SCIENCE COMMITTEE CHARTER

This Science Committee Charter (the “*Charter*”) was adopted by the Board of Directors (the “*Board*”) of UNITY Biotechnology, Inc., a Delaware corporation (the “*Company*”), on March 14, 2019.

I. Purpose

The purpose of the Science Committee (the “*Committee*”) of the Board is to: (1) assist the Board and management in understanding any emerging or evolving scientific or technological issues of importance to the Company; (2) assist the Board in understanding the status and progress of certain of the Company’s research and development programs; (3) advise management of the Company on certain aspects of the Company’s technology development, as required to achieve its long-term strategic technology development objectives; and (4) assist the Board in understanding the Company’s intellectual property position in connection with the foregoing and otherwise.

II. Membership

The Board shall appoint the members of the Committee. The Committee shall be composed of at least two (2), and up to three (3) non-management members of the Board, one of whom may be designated as Chairperson of the Committee (the “*Chair*”). Each member of the Committee shall (i) have experience in the business judgment of the Board that would be helpful in addressing the matters delegated to the Committee including adequate industrial, academic and/or practical experience with the R&D of (bio)pharmaceuticals, and (ii) be free from any relationship that, in the judgment of the Board, would interfere with his or her exercise of business judgment as a Committee member. The Board may designate one or more members of the Board as alternative members of the Committee, who may replace any absent or disqualified member or members at any meetings of the Committee.

III. Responsibilities

1. When and as requested by the Board, the Committee shall:
 - a. Review, evaluate and advise the Board on the overall strategy, direction and effectiveness of the Company’s research and development programs and related investments, and on the Company’s progress in achieving its long-term strategic research and development goals and objectives.
 - b. Monitor and evaluate trends in research and development, and report to the Board and management regarding emerging technologies for building the Company’s technological strength.
 - c. Evaluate and advise the Board and management on the soundness, opportunities and risks associated with the products, programs and technologies in which the Company is, or is considering, investing its research and development efforts.
 - d. Review and advise the Board on the Company’s current and potential internal and external programs and investments in science and technology. For any external programs and investments in products and technologies (e.g., potential licenses, acquisitions, collaborations or equity investments) that require approval by the full Board, the Committee may be asked to provide the Board and management with its advice prior to such Board action.

- e. Regularly review and make recommendations to the Board and management with respect to the Company's research and development pipeline.

IV. Subject Matter Experts

The Committee may retain, as needed, specific subject-matter experts or advisors to assist the Committee in meeting its purposes and responsibilities. The Committee shall have direct access to the Company's personnel to solicit data and advice in connection with the Committee's review of the Company's research and development programs, manufacturing and regulatory strategies and business development opportunities.

V. Procedures and Administration

1. The Committee shall meet as often as it deems necessary in order to perform its responsibilities, but not less than three (3) times per year.
2. All non-management directors who are not members of the Committee may attend all meetings of the Committee.
3. The Committee shall keep such records of its meetings as it shall deem appropriate.
4. The Committee shall report regularly to the Board and copies of all Committee presentations and materials shall be made available to the Board.
5. With the exception of agenda items reserved for the Committee's internal discussion at each meeting, the Chief Scientific Officer and Chief Medical Officer are expected to attend each meeting of the Committee.
6. The Committee may form and delegate authority to one or more subcommittees (including a subcommittee consisting of a single member) as it deems appropriate from time to time under the circumstances.
7. The Committee shall, from time to time as it deems appropriate, review and reassess the adequacy of this Charter and recommend any proposed changes to the Board for approval.
8. The Committee is authorized, without further action by the Board, to engage such independent legal and other advisors as it deems necessary or appropriate to carry out its responsibilities. Such independent advisors may be the regular advisors to the Company. The Committee is empowered, without further action by the Board, to cause the Company to pay the compensation of such advisors as established by the Committee.
9. The Committee shall have the authority to conduct or authorize investigations into any matters within the scope of its responsibilities as it shall deem appropriate, including the authority to request any officer, employee or advisor of the Company to meet with the Committee or any advisors engaged by the Committee.
10. The Committee shall periodically evaluate its own performance.